Literature DB >> 29549484

Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter?

Mariana Andozia Morini1, Roberto Lodeiro Muller2, Paulo César Barbosa de Castro Junior2, Rafael José de Souza2, Eliney Ferreira Faria2.   

Abstract

INTRODUCTION: Prostate cancer (PC) most of the time presents with an indolent course. Thus, delays in treatment due to any causes might not affect long-term survival and may not affect cancer cure rates.
PURPOSE: In this study, we evaluated the effect of delay-time between PC diagnosis and radical prostatectomy regarding oncological outcomes: Gleason score upgrade on surgical specimen, pathologic extracapsular extension (ECE) on surgical specimen, and postoperative biochemical recurrence (BCR) on follow-up.
METHODS: We evaluated PC patients who underwent radical prostatectomy (RP) regarding clinical and pathological findings and theirs respective interval between diagnosis and surgical treatment measured in days and months. We used univariate and multivariate logistic regression to evaluate the impact of interval-time.
RESULTS: A total of 908 PC patients underwent RP between 2006 and 2014. Mean age was 61.5 years, the mean time-to-surgery was 191 days (> 6 months) and 187 (20.5%) patients had BCR, with a mean follow-up of 44 months. According to our analysis, no statistically significant maximum cut-off time interval between diagnostic biopsy and surgery could be established (p = 0.215). Regardless of interval-time: ≤ 6 months (56.5%), 6-12 months (38.5%), and > 12 months (5.1%) after biopsy, we found no time interval correlated with poor oncological outcomes. This study has several limitations. It was retrospective and had a mean follow-up of 4 years. Additional follow-up is necessary to determine whether these findings will be maintained over time.
CONCLUSIONS: We showed that the time between diagnosis and surgical treatment did not affect the oncological outcomes in our study.

Entities:  

Keywords:  Oncological outcomes; Pathological findings; Prostate cancer; Radical prostatectomy

Mesh:

Substances:

Year:  2018        PMID: 29549484     DOI: 10.1007/s00345-018-2251-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  28 in total

1.  A simple method for calculating power based on a prior trial.

Authors:  George F Borm; Bastiaan R Bloem; Marten Munneke; Steven Teerenstra
Journal:  J Clin Epidemiol       Date:  2010-06-22       Impact factor: 6.437

2.  Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.

Authors:  Timothy J Wilt; Karen M Jones; Michael J Barry; Gerald L Andriole; Daniel Culkin; Thomas Wheeler; William J Aronson; Michael K Brawer
Journal:  N Engl J Med       Date:  2017-07-13       Impact factor: 91.245

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

4.  Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.

Authors:  Niall M Corcoran; Matthew K H Hong; Rowan G Casey; Antonio Hurtado-Coll; Justin Peters; Laurence Harewood; S Larry Goldenberg; Chris M Hovens; Anthony J Costello; Martin E Gleave
Journal:  BJU Int       Date:  2011-03-28       Impact factor: 5.588

5.  Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?

Authors:  Markus Graefen; Jochen Walz; K-H F Chun; Thorsten Schlomm; Alexander Haese; Hartwig Huland
Journal:  Eur Urol       Date:  2005-03-02       Impact factor: 20.096

6.  Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; M Weinstein; J E Tomaszewski; D Schultz; M Rhude; S Rocha; A Wein; J P Richie
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

7.  Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.

Authors:  Toni K Choueiri; Ming-Hui Chen; Anthony V D'Amico; Leon Sun; Paul L Nguyen; Julia H Hayes; Cary N Robertson; Philip J Walther; Thomas J Polascik; David M Albala; Judd W Moul
Journal:  Cancer       Date:  2010-04-15       Impact factor: 6.860

8.  Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy.

Authors:  Robert K Nam; Michael A S Jewett; Murray D Krahn; Michael A Robinette; John Tsihlias; Ants Toi; Minnie Ho; Andrew Evans; Joan Sweet; John Trachtenberg
Journal:  Can J Urol       Date:  2003-06       Impact factor: 1.344

9.  Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer.

Authors:  Stephen J Freedland; Christopher J Kane; Christopher L Amling; William J Aronson; Joseph C Presti; Martha K Terris
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

10.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

View more
  9 in total

1.  One-Stop MRI and MRI/transrectal ultrasound fusion-guided biopsy: an expedited pathway for prostate cancer diagnosis.

Authors:  Alessandro Tafuri; Akbar N Ashrafi; Suzanne Palmer; Aliasger Shakir; Giovanni E Cacciamani; Atsuko Iwata; Tsuyoshi Iwata; Jie Cai; Akash Sali; Chhavi Gupta; Luis G Medina; Mariana C Stern; Vinay Duddalwar; Manju Aron; Inderbir S Gill; Andre Abreu
Journal:  World J Urol       Date:  2019-06-07       Impact factor: 4.226

2.  Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study.

Authors:  Shivanshu Awasthi; Travis Gerke; Jong Y Park; Francis A Asamoah; Vonetta L Williams; Angelina K Fink; Rajesh Balkrishnan; David I Lee; S Bruce Malkowicz; Priti Lal; Jasreman Dhillon; Julio M Pow-Sang; Timothy R Rebbeck; Kosj Yamoah
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-11-09       Impact factor: 4.254

3.  Does time interval between prostate biopsy and surgery affect outcomes of radical prostatectomy? A systematic review and meta-analysis.

Authors:  Jie Li; Qing Jiang; Qiubo Li; Yuanfeng Zhang; Liang Gao
Journal:  Int Urol Nephrol       Date:  2019-11-30       Impact factor: 2.370

4.  Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

Authors:  Kirsti Aas; Sophie Dorothea Fosså; Rune Kvåle; Bjørn Møller; Tor Åge Myklebust; Ljiljana Vlatkovic; Stig Müller; Viktor Berge
Journal:  World J Urol       Date:  2018-11-27       Impact factor: 4.226

5.  Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology.

Authors:  Peter Donato; Matthew J Roberts; Andrew Morton; Samuel Kyle; Geoff Coughlin; Rachel Esler; Nigel Dunglison; Robert A Gardiner; John Yaxley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-19       Impact factor: 9.236

6.  The role of fatal family history and mode of inheritance in prostate cancer for long-term outcomes following radical prostatectomy.

Authors:  Valentin H Meissner; Jamila G H Strüh; Martina Kron; Lea A Liesenfeld; Stephanie Kranz; Jürgen E Gschwend; Kathleen Herkommer
Journal:  World J Urol       Date:  2020-03-11       Impact factor: 4.226

7.  Sociodemographic and Geographic Disparities of Prostate Cancer Treatment Delay in Tennessee: A Population-Based Study.

Authors:  Francisco A Montiel Ishino; Emmanuel A Odame; Kevin Villalobos; Claire Rowan; Martin Whiteside; Hadii Mamudu; Faustine Williams
Journal:  Am J Mens Health       Date:  2021 Nov-Dec

8.  Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review.

Authors:  Ekaterina Laukhtina; Reza Sari Motlagh; Keiichiro Mori; Fahad Quhal; Victor M Schuettfort; Hadi Mostafaei; Satoshi Katayama; Nico C Grossmann; Guillaume Ploussard; Pierre I Karakiewicz; Alberto Briganti; Mohammad Abufaraj; Dmitry Enikeev; Benjamin Pradere; Shahrokh F Shariat
Journal:  World J Urol       Date:  2021-05-28       Impact factor: 4.226

9.  What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer.

Authors:  Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore
Journal:  Clin Oncol Res       Date:  2020-06-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.